Infliximab for the Treatment of Inflammatory Labyrinthitis: A Retrospective Cohort Study
Authors:
- Cassandre DjianCDCassandre Djian
- Karine ChampionKCKarine Champion
- Nicolas LaiNLNicolas Lai
- Ludovic DrouetLDLudovic Drouet
- Blanca Amador BorreroBBBlanca Amador Borrero
- Audrey DepondADAudrey Depond
- Stéphane MoulyStéphane Mouly
- Clément JourdaineCJClément Jourdaine
- Philippe HermanPHPhilippe Herman
- Michael EliezerMEMichael Eliezer
- Charlotte HautefortCHCharlotte Hautefort
- Damien SèneDSDamien Sène
Open Access
- 28 June 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (13) , 4350
Abstract
Inflammatory labyrinthitis is defined as a fluctuant vestibulo-cochlear syndrome associated with an impairment of the blood-labyrinthine barrier (BLB) on delayed FLAIR MRI sequences. Systemic and intratympanic corticosteroids are the gold standard treatment but their effect is frequently insufficient. The objective is here to determine whether infliximab could be of value in the treatment of bilateral inflammatory labyrinthitis. A retrospective monocentric study was conducted between January 2013 and December 2021. All patients included in the study were affected with a bilateral vestibulo-cochlear syndrome associated with bilateral blood-labyrinthine barrier impairment. Patients were administered infliximab at the dose of 5 mg/kg every 6 weeks for 6 months. Audiometry, MRI with delayed FLAIR sequences on the labyrinth, and corticosteroid doses still required were assessed both before and after treatment with infliximab was completed. Pure-tone average (PTA) was the primary outcome. The secondary outcomes were the speech recognition threshold (SRT), the Dizziness Handicap Inventory (DHI) score, and the corticosteroid (CS) dose. A total of nine patients including five men and four women were enrolled in the study. Thirteen ears were analyzed. After a 6-month period of treatment, the mean PTA (54 ± 24 db versus 66 ± 22 db; p = 0.027), SRT (54 ± 37 db versus 66 ± 32 db; p = 0.041) and DHI score (27 ± 15 versus 9 ± 2; p = 0.032) significantly improved. After the 6-month treatment period, the mean CS dose decreased from 38 ± 33 to 6 ± 5 mg/day (p = 0.003). We conclude that infliximab substantially improves the vestibulo-cochlear function in patients with bilateral inflammatory labyrinthitis and could be of value in corticosteroid-dependent cases.Keywords
This publication has 23 references indexed in Scilit:
- Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2016
- Infliximab for autoimmune inner ear disease: case report and literature reviewThe Journal of Laryngology & Otology, 2013
- Severe deafness associated with Crohn's disease and spondylarthropathy: successful treatment with anti-TNFRheumatology, 2012
- Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issuesExpert Opinion on Drug Safety, 2008
- Etanercept, a tumour necrosis factor α receptor antagonist, and methotrexate in acute sensorineural hearing lossThe Journal of Laryngology & Otology, 2006
- Etanercept Treatment for Autoimmune Inner Ear Disease: Results of a Pilot Placebo-Controlled StudyOtology & Neurotology, 2005
- Etanercept therapy for immune-mediated cochleovestibular disorders: A multi-center, open-label, pilot studyArthritis & Rheumatism, 2005
- Histopathology of Idiopathic Chronic Recurrent VertigoThe Laryngoscope, 1996
- Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing lossThe Laryngoscope, 1990
- The Development of the Dizziness Handicap InventoryJAMA Otolaryngology–Head & Neck Surgery, 1990